Talha Badar, Associate Professor of Medicine at Mayo Clinic, shared on X:
“New in Blood Journal: A comprehensive preclinical study evaluated ziftomenib using leukemia cell lines, primary patient samples, xenografts/PDXs, gene-expression profiling, and structural crystallography.
Ziftomenib suppressed MEIS1/HOXA signaling, induced differentiation, and caused leukemia regression in NPM1m/KMT2Ar models.
CRISPR-engineered MEN1-mutant models showed retained activity against T349M and G331R – but resistance with M327I/G331D.”
Title: Discovery and preclinical activity of the menin-KMT2A inhibitor ziftomenib in acute leukemia models
Authors: Hongzhi Miao, Tao Wu, Trupta Purohit, Dong Chen, Szymon Klossowski, Dmitry Borkin, Bradley Clegg, Joshua Ray, SeRa Park, Rhiannon Stevens, EunGi Kim, Katarzyna Kempinska, Yi Wang, Miao He, Bo Wen, Joshua W. Goldman, Jennifer Agrusa, Chao Ding, Maria-Luisa Sulis, Duxin Sun, Rajen Mody, Annette S. Kim, Pingda Ren, Lian-Sheng Li, Yi Liu, Francis Burrows, Linda Kessler, Tomasz Cierpicki, Jolanta Grembecka
Other articles featuring Talha Badar on OncoDaily.